Preventing Macular Edema After Cataract Surgery with Ranibizumab
Author Information
Author(s): Patricia Udaondo, Maria Garcia-Pous, Salvador Garcia-Delpech, David Salom, Manuel Diaz-Llopis
Primary Institution: Nuevo Hospital, Universitario y Politecnico La Fe, Valencia, Spain
Hypothesis
Does intravitreal ranibizumab injection prevent clinically significant macular edema in patients with diabetic retinopathy after cataract surgery?
Conclusion
Intravitreal ranibizumab immediately after cataract surgery significantly reduces the incidence of clinically significant macular edema in patients with diabetic retinopathy.
Supporting Evidence
- 25.92% of patients in the control group developed macular edema compared to only 3.70% in the ranibizumab group at one month post-surgery.
- At three months, 22.22% of the control group had macular edema compared to 3.70% in the ranibizumab group.
- The mean central macular thickness increased significantly in the control group but not in the ranibizumab group.
Takeaway
This study found that giving a special eye injection during cataract surgery helps stop swelling in the eye for people with diabetes.
Methodology
This was a prospective, randomized, controlled study with 54 patients assigned to receive either ranibizumab or no injection during cataract surgery.
Potential Biases
Potential selection bias due to the small number of participants.
Limitations
The study had a short follow-up duration and a small sample size.
Participant Demographics
54 patients, 35 women and 19 men, mean age 70.8 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website